Here’s how Sanofi separates true innovation from all the hype in digital health

Recognizing that digital technology is here to stay in the business of healthcare, pharmaceutical companies have not shied away from collaborating with the folks in Silicon Valley.

Sanofi (NYSE:SNY), for instance, has dove in feet first, striking deals with major tech players like Verily. But weeding out true disruptions from all the noise isn’t easy.

“There’s a lot of hype,” said Rachel Sha, VP of Sanofi’s digital business development & licensing unit. “We work really hard to identify companies that don’t just have nice slides, but actually have early experience and data showing the impact of their technology.”

Get the full story at our sister site, Drug Delivery Business News.

The post Here’s how Sanofi separates true innovation from all the hype in digital health appeared first on MassDevice.

Valeritas touts new data for insulin delivery device

Valeritas (NSDQ:VLRX) touted data today from two new studies of its V-Go wearable insulin delivery device in patients with Type II diabetes.

In one three-month evaluation of 60 people with Type II diabetes, researchers assessed if using V-Go could improve glycemic control in patients who were uncontrolled on prior treatment regimens.

Get the full story at our sister site, Drug Delivery Business News.

The post Valeritas touts new data for insulin delivery device appeared first on MassDevice.

With groundbreaking approval, Amgen launches new class of medicine for migraine patients

Amgen (NSDQ:AMGN) won FDA approval this week for its once-monthly Aimovig injection designed to prevent the onset of migraines in adults.

The drug is the first of its kind – a molecule that blocks the receptor for a protein that is linked to migraine pain, the calcitronin gene-related peptide. Other major pharmaceutical companies like Eli Lilly (NYSE:LLY) and Teva Pharmaceuticals (NYSE:TEVA) are working on their own CGRP product, but Amgen’s is the first to hit the market.

Get the full story at our sister site, Drug Delivery News.

The post With groundbreaking approval, Amgen launches new class of medicine for migraine patients appeared first on MassDevice.

West Pharmaceutical boosts its analytical services with new technology

West Pharmaceutical Services (NYSE:WST) has expanded its analytical services capabilities with new equipment to help address the pharmaceutical industry’s packaging and drug-delivery concerns, the company said today.

West specifically highlighted its addition of an ion mobility quadrupole time-of-flight mass spectrometer – an instrument that combines chromatography, ion mobility and mass spectrometry.

Get the full story at our sister site, Drug Delivery News.

The post West Pharmaceutical boosts its analytical services with new technology appeared first on MassDevice.

Medtronic launches study of drug-eluting stent as treatment for bifurcation lesions

Medtronic (NYSE:MDT) today launched a study to evaluate the safety and efficacy of its Resolute Onyx drug-eluting stent for the treatment of bifurcation lesions in patients with coronary artery disease.

The medtech giant said that bifurcation lesions make up nearly 20% of all percutaneous coronary interventions. The assessment of DES tech in this patient group is part of Medtronic’s post-approval study of its Resolute Onyx device.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic launches study of drug-eluting stent as treatment for bifurcation lesions appeared first on MassDevice.

Baxter wins FDA nod for Spectrum IQ infusion system

Baxter (NYSE:BAX) said today that it won FDA clearance for its Spectrum IQ infusion system with Dose IQ safety software.

The company touted its system as the first of its kind to include bi-directional electronic medical records integration.

Get the full story at our sister site, Drug Delivery Business News.

The post Baxter wins FDA nod for Spectrum IQ infusion system appeared first on MassDevice.

How Bigfoot Biomedical’s CEO wants to boost diabetes management

Jeffrey Brewer faced the biggest challenge of his life when his 7-year-old son Sean received a diabetes diagnosis in 2002: Diabetes became the new focus for Brewer’s energy.

In his role as CEO at JDRF (formerly the Juvenile Diabetes Research Foundation) between 2011 and 2014, Brewer forged financial partnerships with industry to drive the development of insulin delivery and glucose monitoring technologies. He joined the founding of Bigfoot Biomedical in 2014 because he felt that industry could and should do more to marry the best of our technologies to automate diabetes management and make them available to the greatest number of people in need.

Get the full story at our sister site, Medical Design & Outsourcing.

Brewer returns for a keynote appearance at DeviceTalks Minnesota, June 4–5 in St. Paul, Minn.

The post How Bigfoot Biomedical’s CEO wants to boost diabetes management appeared first on MassDevice.

Pavmed registers for $20m rights offering

Pavmed (NSDQ:PAVM) said today that it filed a preliminary prospectus with the SEC for an offering of the rights to buy a new unit in exchange for each share of outstanding common stock.

The medical device company plans to offer the rights to purchase up to 9 million units at $2.25 apiece on May 21, valuing the offering at $20.3 million.

Get the full story at our sister site, Drug Delivery Business News.

The post Pavmed registers for $20m rights offering appeared first on MassDevice.

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial

OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer.

The trial is slated to study the drug-device combination in patients with inoperable locally advanced or metastatic cancer who have failed at least one systemic chemotherapy or immunotherapy.

Get the full story at our sister site, Drug Delivery Business News.

The post OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial appeared first on MassDevice.

J&J’s Janssen touts Ph3 data for antidepressant nasal spray

Johnson & Johnson‘s (NYSE:JNJJanssen revealed data today from two Phase III trials of its investigational esketamine nasal spray in patients with treatment-resistant depression.

The Titusville, N.J.-based company said that if approved by the FDA, esketamine would represent one of the first new approaches designed to treat refractory major depressive disorder in the last 50 years.

Get the full story at our sister site, Drug Delivery Business News.

The post J&J’s Janssen touts Ph3 data for antidepressant nasal spray appeared first on MassDevice.